Akebia Therapeutics, Inc. (AKBA): who owns it and who trades it
As of Nov 16, 2026, AKBA insiders reported 16 open-market sales worth $963K and 1 purchase worth $86.6K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was John P. Butler (CEO), with $474K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Akebia Therapeutics
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, AKBA insiders reported $86.6K of open-market purchases and $963K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Erik Ostrowski | CFO | Sale | 56,019 | $1.11 | $62.2K | Form 4 |
| Mar 4, 2026 | John P. Butler | CEO | Purchase | 69,270 | $1.25 | $86.6K | Form 4 |
| Feb 2, 2026 | Richard C Malabre | Vice president | Sale | 13,382 | $1.39 | $18.6K | Form 4 |
| Feb 2, 2026 | Richard C Malabre | Vice president | Sale | 36,142 | $1.39 | $50.2K | Form 4 |
| Feb 2, 2026 | Nicholas Grund | Chief Commercial Officer | Sale | 53,585 | $1.39 | $74.5K | Form 4 |
| Feb 2, 2026 | Nicholas Grund | Chief Commercial Officer | Sale | 31,244 | $1.39 | $43.4K | Form 4 |
| Feb 2, 2026 | Steven Keith Burke | Vice president | Sale | 25,375 | $1.39 | $35.3K | Form 4 |
| Feb 2, 2026 | Steven Keith Burke | Vice president | Sale | 21,582 | $1.39 | $30K | Form 4 |
| Feb 2, 2026 | Steven Keith Burke | Vice president | Sale | 20,701 | $1.39 | $28.8K | Form 4 |
| Feb 2, 2026 | Carolyn M. Rucci | Vice president | Sale | 16,846 | $1.39 | $23.4K | Form 4 |
| Feb 2, 2026 | Carolyn M. Rucci | Vice president | Sale | 25,382 | $1.39 | $35.3K | Form 4 |
| Feb 2, 2026 | Carolyn M. Rucci | Vice president | Sale | 27,544 | $1.39 | $38.3K | Form 4 |
| Feb 2, 2026 | Erik Ostrowski | CFO | Sale | 34,951 | $1.39 | $48.6K | Form 4 |
| Feb 2, 2026 | John P. Butler | CEO | Sale | 83,689 | $1.39 | $116K | Form 4 |
| Feb 2, 2026 | John P. Butler | CEO | Sale | 114,891 | $1.39 | $160K | Form 4 |
| Feb 2, 2026 | John P. Butler | CEO | Sale | 96,065 | $1.39 | $134K | Form 4 |
| Feb 2, 2026 | John P. Butler | CEO | Sale | 46,660 | $1.39 | $64.9K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| John P. Butler | CEO and President, Director | $86.6K | $474K | Mar 4, 2026 |
| Nicholas Grund | Chief Commercial Officer | – | $118K | Feb 2, 2026 |
| Erik Ostrowski | SVP, CFO, CBO & Treasurer | – | $111K | Jun 29, 2026 |
| Carolyn M. Rucci | SVP, Chief Legal Officer | – | $97K | Feb 2, 2026 |
| Steven Keith Burke | SVP, Chief Medical Officer | – | $94K | Feb 2, 2026 |
| Richard C Malabre | SVP, Chief Accounting Officer | – | $68.8K | Feb 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AKBA short interest
Moderate short interest. 9.8% of AKBA shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 3%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 27.20M AKBA shares were sold short, 9.8% of the shares outstanding, up 17.9% from the report before. At the average daily volume of 9.05M shares, buying them all back would take about 3.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 27.20M | 9.82% | +18% | 9.05M | 3.0 |
| Oct 15, 2026 | 23.07M | 8.33% | +3% | 7.79M | 3.0 |
| Sep 30, 2026 | 22.48M | 8.11% | +10% | 6.41M | 3.5 |
| Sep 15, 2026 | 20.50M | 7.40% | -11% | 7.44M | 2.8 |
| Aug 31, 2026 | 23.00M | 8.30% | +8% | 9.83M | 2.3 |
| Aug 14, 2026 | 21.37M | 7.71% | +11% | 6.04M | 3.5 |
| Jul 31, 2026 | 19.18M | 6.92% | +1% | 2.18M | 8.8 |
| Jul 15, 2026 | 19.08M | 7.11% | -1% | 4.54M | 4.2 |
| Jun 30, 2026 | 19.18M | 7.15% | -34% | 7.12M | 2.7 |
| Jun 15, 2026 | 29.20M | 10.89% | +6% | 5.21M | 5.6 |
| May 29, 2026 | 27.42M | 10.22% | +4% | 6.62M | 4.1 |
| May 15, 2026 | 26.37M | 9.83% | -5% | 4.64M | 5.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Akebia Therapeutics company events
Akebia Therapeutics filed 13 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 23, 2026ListingAkebia Therapeutics, Inc. received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.00001 per share, had closed below $1.00 per… Filing
- Oct 14, 2026LeadershipNicholas Grund, Senior Vice President and Chief Commercial Officer of Akebia Therapeutics, Inc., notified the Company of his decision to resign his employment with the Company for personal reasons. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 30, 2026AnnouncementThe Company and USRC announced the results of a planned interim analysis of the VOICE trial and that it met the predefined stopping criteria by establishing non-inferiority and superiority of the primary composite endpoint and the decision by USRC Kidney Research to stop the trial on this basis. Filing
- Jun 22, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 1, 2026LeadershipReported a change among its top officers or directors, or their pay. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 30, 2026LeadershipThe Company entered into an amended and restated executive severance agreement with the Company’s President and Chief Executive Officer, John P. Butler. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 1, 2025AgreementAkebia Therapeutics, Inc. entered into an Asset Purchase Agreement with Q32 Bio Inc. and Q32 Bio Operations Inc. (together, “Q32”), pursuant to which Q32 sold and assigned to the Company, and the Company purchased and assumed from Q32, substantially all assets and liabilities of Q32 and its… Filing
- Nov 17, 2025AgreementAs previously disclosed, on May 24, 2023, Akebia Therapeutics, Inc. and MEDICE Arzneimittel Putter GmbH & Co. KG entered into a License Agreement pursuant to which the Company granted to Medice an exclusive license to develop and commercialize Vafseo for the treatment of anemia in patients with… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Akebia Therapeutics financials
Famous investors that hold AKBA
4 of the 50 well-known investors we track reported holding AKBA in their latest 13F filing. The largest position is Jim Simons's, worth $1.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.88M | $1.7M | 0.0% | +54% |
| Israel Englander · Millennium Management | Q3 2026 | 1.79M | $1.6M | 0.0% | -44% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.33M | $1.2M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.04M | $958K | 0.0% | -39% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Akebia Therapeutics, Inc. (AKBA) stock
Are AKBA insiders buying or selling?
In the last 12 months, AKBA insiders reported 1 open-market purchase worth $86.6K and 16 sales worth $963K. The latest trade was on Jun 29, 2026. See every trade.
What is the short interest in AKBA?
As of Oct 30, 2026, 27.20M AKBA shares were sold short, 9.8% of the shares outstanding, up 17.9% from the report before. At the average daily volume of 9.05M shares, buying them all back would take about 3.0 trading days (days to cover). See the history.
Which famous investors hold AKBA?
4 of the 50 well-known investors we track reported AKBA in their latest 13F filing, including Jim Simons, Israel Englander, Steve Cohen. The largest position is worth $1.7M. See all holders.
Executive pay
Akebia Therapeutics's chief executive was paid a total of $5.7M for the year ended Dec 31, 2025, up 33% from $4.3M the year before. In the last 12 months, Akebia Therapeutics's executives and directors bought $86.6K of stock on the open market and sold $963K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.